Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Revisjonsdato Publiseringsdato
Utgiver(e) Redaktør Publikasjonstype
  • Norsk tittel - Nasjonal retningslinje for gravide i legemiddelassistert rehabilitering (LAR) og oppfølging av familiene frem til barnet når skolealder
  • Engelsk tittel -
  • Versjon - 2
  • Status - Publisert
  • IS-nr - 1876
  • ISBN - 978-82-8081-221-6
  • DOI -
  • Revisjonsdato - 02.01.2012
  • Neste revisjon -
  • Publikasjonsdato - 02.05.2011
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør - Brittelise Bakstad og Gabrielle Welle-strand
  • Publikasjonstype - Nasjonale retningslinjer
Vedlegg
 
  1. Nasjonal retningslinje for legemiddelassistert rehabilitering ved opioidavhengighet. Oslo: Helsedirektoratet; 2010. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/nasjonal-retningslinje-for-legemiddelassistert-rehabilitering-ved-opioidavhengighet/Publikasjoner/Nasjonal-retningslinje-for-legemiddelassistert-rehabilitering-ved-opioidavhengighet-konvertert.pdf .
  2. Berg RC, Kornør H, Øverland S, Smedslund G, Hammerstrøm KT, Storetvedt K, et al. Medikamentell vedlikeholdsbehandling av gravide med opioidavhengighet. Oslo: Kunnskapssenteret; 2008. Rapport fra Kunnskapssenteret 31-2008. Tilgjengelig fra: http://www.kunnskapssenteret.no/Publikasjoner/4754.cms
  3. Spigset O, Aamo TO. Legemiddelassistert rehabilitering og amming. Trondheim: 2008.
  4. Dole VP, Nyswander ME. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965;8(23):646-50.
  5. Newman RG, Bashkow S, Calko D. Results of 313 consecutive live births of infants delivered to patients in the New York City Methadone Maintenance Treatment Program. Am J Obstet Gynecol 1975;121(2):233-7.
  6. Stimmel B, Goldberg J, Reisman A, Murphy RJ, Teets K. Fetal outcome in narcotic-dependent women: the importance of the type of maternal narcotic used. Am J Drug Alcohol Abuse 1982;9(4):383-95.
  7. Kandall SR, Albin S, Gartner LM, Lee KS, Eidelman A, Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977;1(2):159-69.
  8. Stimmel B, Adamsons K. Narcotic dependency in pregnancy. Methadone maintenance compared to use of street drugs. JAMA 1976;235(11):1121-4.
  9. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998;25(1):139-51.
  10. Jansson LM, Svikis D, Lee J, Paluzzi P, Rutigliano P, Hackerman F. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat 1996;13(4):321-9.
  11. Jansson LM, Svikis DS, Velez M, Fitzgerald E, Jones HE. The impact of managed care on drug-dependent pregnant and postpartum women and their children. Subst Use Misuse 2007;42(6):961-74.
  12. Fischer G, Eder H, Jagsch R, Lennkh A, Habeier A, Aschauer H, et al. Maintenance therapy with synthetic opioids within a multidisciplinary program - A stabilizing necessity for pregnant opioid dependent women. Arch Womens Ment Health 1998;3(1):109-16.
  13. Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000;95(2):239-44.
  14. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S, Groupe d'Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006;82(3):250-7.
  15. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79(1):1-10.
  16. Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006;101(2):275-81.
  17. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363(24):2320-31.
  18. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009. Tilgjengelig fra: http://whqlibdoc.who.int/publications/2009/9789241547543_eng.pdf .
  19. Fischer G, Kopf N. Review of the literature on pregnancy and psychosocially assisted pharmacotherapy of opioid dependence (including withdrawal management, agonist and antagonist maintenance therapy and adjuvant pharmacotherapy). Geneva: World Health Organization; 2007. Tilgjengelig fra: http://www.who.int/substance_abuse/activities/pregnancy.pdf .
  20. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008;103(9):1429-40.
  21. Winklbaur B, Jung E, Fischer G. Opioid dependence and pregnancy. Curr Opin Psychiatry 2008;21(3):255-9.
  22. Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008;35(3):245-59.
  23. Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, et al. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict 2010;19(5):416-21.
  24. Jansson LM, Dipietro JA, Velez M, Elko A, Williams E, Milio L, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2010;33(2):240-3.
  25. Stine SM, Heil SH, Kaltenbach K, Martin PR, Coyle MG, Fischer G, et al. Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study. Am J Drug Alcohol Abuse 2009;35(6):429-33.
  26. Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, et al. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat 2011;40(2):199-202.
  27. Minozzi S, Amato L, Vecchi S, Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008;(2):CD006318.
  28. Wang EC. Methadone treatment during pregnancy. J Obstet Gynecol Neonat Nurs 1999;28(6):615-22.
  29. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009;5(1):47-55.
  30. Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact 2004;20(1):62-71.
  31. Baxter FR, Nerhood R, Chaffin D. Characterization of babies discharged from Cabell Huntington Hospital during the calendar year 2005 with the diagnoses of neonatal abstinence syndrome. W V Med J 2009;105(2):16-21.
  32. Jones HE, Kaltenbach K, O'Grady KE. The complexity of examining developmental outcomes of children prenatally exposed to opiates. A response to the Hunt et al. Adverse neurodevelopmental outcome of infants exposed to opiates in-utero. Early Hum Dev 2009;85(4):271-2.
  33. Svikis DS, Golden AS, Huggins GR, Pickens RW, McCaul ME, Velez ML, et al. Cost-effectiveness of treatment for drug-abusing pregnant women. Drug Alcohol Depend 1997;45(1-2):105-13.
  34. Kaltenbach K, Jones HE, Fischer G, Selby P. New approaches in the treatment of opioid dependency during pregnancy. Heroin Addict Relat Clin Probl 2007;9(3):9-20.
  35. Lundgren LM, Fitzgerald T, Young N, Amodeo M, Schilling RF. Medication assisted drug treatment and child well-being. Child Youth Serv Rev 2007;29(8):1051-69.
  36. Jones HE, Haug N, Silverman K, Stitzer M, Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend 2001;61(3):297-306.
  37. Svikis DS, Lee JH, Haug NA, Stitzer ML. Attendance incentives for outpatient treatment: effects in methadone- and nonmethadone-maintained pregnant drug dependent women. Drug Alcohol Depend 1997;48(1):33-41.
  38. Jones HE, Svikis D, Rosado J, Tuten M, Kulstad JL. What if they do not want treatment?: lessons learned from intervention studies of non-treatment-seeking, drug-using pregnant women. Am J Addict 2004;13(4):342-57.
  39. Jones HE, Svikis DS, Tran G. Patient compliance and maternal/infant outcomes in pregnant drug-using women. Subst Use Misuse 2002;37(11):1411-22.
  40. Jansson LM, Svikis DS, Beilenson P. Effectiveness of child case management services for offspring of drug-dependent women. Subst Use Misuse 2003;38(14):1933-52.
  41. Konijnenberg C, Melinder A. Prenatal exposure to methadone and buprenorphine: A review of the potential effects on cognitive development. Child Neuropsychol 2011;17(5):495-519.
  42. Sarman I. Metadonbehandling under graviditet och dess effekter på barnet. Bättre än fortsatt missbruk, bör följas av specialiserad modravårdscentral. Läkartidningen 2000;97(18):2182-4, 2187-8, 2190.
  43. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008;96(1-2):69-78.
  44. Olofsson M, Buckley W, Andersen GE, Friis-Hansen B. Investigation of 89 children born by drug-dependent mothers. II. Follow-up 1-10 years after birth. Acta Paediatr Scand 1983;72(3):407-10.
  45. Kahila H, Stefanovic V, Loukovaara M, Alfthan H, Hamalainen E, Halmesmaki E. Prenatal buprenorphine exposure: effects on biochemical markers of hypoxia and early neonatal outcome. Acta Obstet Gynecol Scand 2008;87(11):1213-9.
  46. Hytinantti T, Kahila H, Renlund M, Jarvenpaa AL, Halmesmaki E, Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr 2008;97(8):1040-4.
  47. Sarkola T, Kahila H, Gissler M, Halmesmaki E. Risk factors for out-of-home custody child care among families with alcohol and substance abuse problems. Acta Paediatr 2007;96(11):1571-6.
  48. Salo S, Politi J, Tupola S, Biringen Z, Kalland M, Halmesmaki E. Early development of opioid-exposed infants born to mothers in buprenorphine-replacement therapy. J Reprod Infant Psychol 2010;28(2):161-79.
  49. Kahila H, Saisto T, Kivitie-Kallio S, Haukkamaa M, Halmesmaki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand 2007;86(2):185-90.
  50. Finnegan L, Winklbaur B, Fischer G, Olofsson M, Welle-Strand GK. New Approaches in the treatment of opioid dependency during pregnancy. Heroin Addict Relat Clin Probl 2009;11(2):47-57.
  51. Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res 2009;15(3):128-34.
  52. Sarfi M, Martinsen H, Bakstad B, Roislien J, Waal H. Patterns in sleep-wakefulness in three-month old infants exposed to methadone or buprenorphine. Early Hum Dev 2009;85(12):773-8.
  53. Lund IO, Skurtveit S, Sarfi M, Bakstad B, Welle-Strand GK, Ravndal E. Substance use during and after pregnancy among a national cohort of pregnant women in opioid maintenance treatment and their partners. J Subs Use 2011;Epub 24. Aug.
  54. Lund IO, Skurtveit S, Sarfi M, Bakstad B, Welle-Strand GK, Ravndal E. A two-year prospective study of psychological distress among a national cohort of pregnant women in opioid maintenance treatment and their partners. J Subs Use. Under publisering 2011.
  55. Sarfi M, Smith L, Waal H, Sundet JM. Risks and realities: dyadic interaction between 6-month-old infants and their mothers in opioid maintenance treatment. Infant Behav Dev 2011;34(4):578-89.
  56. Sandtorv L, Reigstad H, Bruaroy S, Elgen I, Laegreid LM. Har legemiddelassistert rehabilitering i svangerskapet konsekvenser for barna? Tidsskr Nor Lægeforen 2009;129(4):287-90.
  57. Waaktaar T. Samme risiko - ulikt utfall. Barn av rusmisbrukende foreldre [Nettdokument]. Narvik: forebygging.no [oppdatert 2011; lest 27 Dec 2011]. Tilgjengelig fra: http://www.forebygging.no/en/Teori/Innsatsomrader/Samme-risiko---ulikt-utfall-Barn-av-rusmisbrukende-foreldre-2011/
  58. Kashiwagi M, Arlettaz R, Lauper U, Zimmermann R, Hebisch G. Methadone maintenance program in a Swiss perinatal center: (I): Management and outcome of 89 pregnancies. Acta Obstet Gynecol Scand 2005;84(2):140-4.
  59. Fajemirokun-Odudeyi O, Sinha C, Tutty S, Pairaudeau P, Armstrong D, Phillips T, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006;126(2):170-5.
  60. Kandall SR, Gaines J, Habel L, Davidson G, Jessop D. Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring. J Pediatr 1993;123(1):120-6.
  61. Rosen TS, Johnson HL. Drug-addicted mothers, their infants, and SIDS. Ann N Y Acad Sci 1988;533:89-95.
  62. Blair PS, Sidebotham P, Evason-Coombe C, Edmonds M, Heckstall-Smith EM, Fleming P. Hazardous cosleeping environments and risk factors amenable to change: case-control study of SIDS in south west England. BMJ 2009;339:b3666.
  63. Burns L, Conroy E, Mattick RP. Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev 2010;29(5):551-6.
  64. Mulvihill AO, Cackett PD, George ND, Fleck BW. Nystagmus secondary to drug exposure in utero. Br J Ophthalmol 2007;91(5):613-5.
  65. McGlone L, Mactier H, Hamilton R, Bradnam MS, Boulton R, Borland W, et al. Visual evoked potentials in infants exposed to methadone in utero. Arch Dis Child 2008;93(9):784-6.
  66. McGlone L, Mactier H, Weaver LT. Drug misuse in pregnancy: losing sight of the baby? Arch Dis Child 2009;94(9):708-12.
  67. Trommald M. Maintenance treatment and pregancy. I: Waal H, Haga E, red. Maintenance treatment of heroin addiction. Evidence at the crossroads. Oslo: Cappelen; 2003. s. 243-53.
  68. Sande HA, Vold I, Lindemann R, Duckert M. Den gravide rusmiddelbruker. Erfaringer fra Kvinneklinikken, Ullevål sykehus, i årene 1980-82. Tidsskr Nor Lægeforen 1985;105(32):2315-8.
  69. Martens A. Hva skjer med gravide rusmiddelmisbrukere? En etterundersøkelse av 31 mødre. Oslo: Sentralrådet for narkotikaproblemer; 1986. Notatserie nr 3 - 86.
  70. Sundfær Aa. Fra rus til mening: en undersøkelse av barna til mødre med tidligere rusproblmer: dagligliv og mestring. Oslo: Barnevernets utviklingssenter; 1992. Rapport 3:1992.
  71. Sundfær Aa. Ung og lovende: barna til 31 mødre med rusproblemer i svangerskapet er blitt ungdommer: tredje gangs etterundersøkelse med fokus på utvikling og mestring i familien, skole og fritid. Oslo: Oslo kommune, Barne- og familieetaten Rusmiddeldirektoratet; 1999.
  72. Sundfær Aa. 31 kvinner med rusproblemer fikk barn - hvordan gikk det? Tidsskr Nor Lægeforen 2001;121(1):73-5.
  73. Sundfær Aa. Barna til 31 kvinner med rusproblemer er blitt 20 år. Hvordan har det gått? Oslo: Regionsenter for barne- og ungdomspsykiatri, Helseregion øst + sør Ullevål universitetssykehus; 2004.
  74. Sundfær Aa. Voksenliv i lys av foreldrenes rusmisbruk. Oslo: Oslo Univeristetssykehus HF, Klinikk for psykisk helse - Barn og ungdom; 2009. Monografiserien 29.
  75. Moe V. A prospective, longitudinal study of children prenatally exposed to drugs: prediction and developmental outcome at 4 1/2 years. Oslo: Psykologisk institutt, Universitetet i Oslo; 2002.
  76. Slinning K. A prospective, longitudinal study of children prenatally exposed to substances: With special emphasis on attention and self-regulation. Oslo: Psykologisk institutt, Universitetet i Oslo; 2003.
  77. Slinning K. Foster placed children prenatally exposed to poly-substances--attention-related problems at ages 2 and 4 1/2. Eur Child Adolesc Psychiatry 2004;13(1):19-27.
  78. Walhovd KB, Moe V, Slinning K, Due-Tonnessen P, Bjornerud A, Dale AM, et al. Volumetric cerebral characteristics of children exposed to opiates and other substances in utero. Neuroimage 2007;36(4):1331-44.
  79. Dalen K, Bruaroy S, Wentzel-Larsen T, Laegreid LM. Cognitive functioning in children prenatally exposed to alcohol and psychotropic drugs. Neuropediatrics 2009;40(4):162-7.
  80. Söderström K. Mental preparation during pregnancy in women with substance addiction: a qualitative interview-study. Child Fam Soc Work 2011;Epub 13. sept.
  81. Söderström K, Skårderud F. Minding the baby. Mentalization-based treatment in families with parental substance use disorders: Theoretical framework. Nordic Psychology 2009;61(3):47-65.
  82. Söderström K. Dragkamp mellom håp og fortvilelse: rusavhengige kvinners opplevelse av graviditet og foreldreskap. I: Straand S, red. Samhandling som omsorg: tverrfaglig psykososialt arbeid med barn og unge. Oslo: Kommuneforlaget; 2011. s. 197-219.
  83. Söderström K. The Good, the Bad and the Invisible Father. Figures of fatherhood in men with substance use disorders: A phenomenological study. Fathering. Under publisering 2012.
  84. Metodebok for utarbeidelse av nasjonale retningslinjer. Oslo: Helsedirektoratet; 2009.
  85. Hjerkinn B, Lindaek M, Rosvold EO. Substance abuse in pregnant women. Experiences from a special child welfare clinic in Norway. BMC Public Health 2007;(7):322.
  86. Background papers to the National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn. Sydney: NSW Department of Health; 2006. Tilgjengelig fra: http://www.health.nsw.gov.au/pubs/2006/pdf/bgpapers_drugs_pregnancy.pdf .
  87. Bell J, Ali R. National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn. Sydney: NSW Department of Health; 2006. Tilgjengelig fra: http://www.health.nsw.gov.au/pubs/2006/pdf/ncg_druguse.pdf .
  88. Medication-Assisted Treatment For Opioid Addiction In Opioid Treatment Programs. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2008. Treatment Improvement Protocol (TIP) Series 43. Tilgjengelig fra: http://store.samhsa.gov/product/TIP-43-Medication-Assisted-Treatment-for-Opioid-Addiction-in-Opioid-Treatment-Programs/SMA08-4214
  89. Retningslinjer for svangerskapsomsorgen. Oslo: Sosial- og helsedirektoratet; 2005. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/nasjonal-faglig-retningslinje-for-svangerskapsomsorgen-fullversjon/Publikasjoner/retningslinjer-for-svangerskapsomsorgen.pdf .
  90. Retningslinjer for svangerskapsomsorgen: kortversjon. Oslo: Sosial- og helsedirektoratet; 2005. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/nasjonal-faglig-retningslinje-for-svangerskapsomsorgen-kortversjon/Publikasjoner/nasjonal-faglig-retningslinje-for-svangerskapsomsorgen-kortversjon.pdf .
  91. Faglige retningslinjer for oppfølging av for tidlig fødte barn. Oslo: Sosial- og helsedirektoratet; 2007. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/nasjonale-faglige-retningslinjer-for-oppfolging-av-for-tidlig-fodte-barn/Publikasjoner/nasjonale-faglige-retningslinjer-for-oppfolging-av-for-tidlig-fodte-barn.pdf .
  92. FNs konvensjon om barnets rettigheter (Barnekonvensjonen). Tilgjengelig fra: http://www.fn.no/content/download/3957/20111/file/FNs%20konvensjon%20om%20barnets%20rettigheter.pdf .
  93. Lov om helsepersonell m.v. (helsepersonelloven). LOV-1999-07-02-64.
  94. Lov om pasientrettigheter (pasientrettighetsloven). LOV-1999-07-02-63.
  95. Lov om spesialisthelsetjenesten m.m. (spesialisthelsetjenesteloven). LOV-1999-07-02-61.
  96. Lov om helsetjenesten i kommunene [kommunehelsetjenesteloven]. LOV-1982-11-19-66.
  97. Lov om legemidler m.v. (legemiddelloven). LOV 1992-12-04 nr 132.
  98. Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV 2011-06-24 nr 30.
  99. Lov om barneverntjenester (barnevernloven). LOV-1992-07-17-100.
  100. Om helsepersonells rett og plikt til å gi opplysninger til barnevern, politi og sosialtjeneste. Oslo: Sosial- og helsedirektoratet; 2006.
  101. Forskrift om legemiddelassistert rehabilitering (LAR-forskriften). FOR 2009-12-18 nr 1641.
  102. Et trygt fødetilbud: kvalitetskrav til fødselsomsorgen. Oslo: Helsedirektoratet; 2010. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/et-trygt-fodetilbud-kvalitetskrav-til-fodselsomsorgen/Publikasjoner/et-trygt-fodetilbud-kvalitetskrav-til-fodselsomsorgen.pdf .
  103. Opptrappingsplan for rusfeltet: opptrappingsplan. Oslo: Helse- og omsorgsdepartemnetet; 2008. Tilgjengelig fra: http://www.regjeringen.no/Upload/HOD/Dokumenter%20FHA/Opptr.plan.pdf .
  104. Helse- og omsorgsdepartementet. En gledelig begivenhet: om en sammenhengende svangerskap-, fødsel- og barselomsorg.  2009. St. meld. nr. 12 (2008-2009). Tilgjengelig fra: http://www.regjeringen.no/pages/2152512/PDFS/STM200820090012000DDDPDFS.pdf
  105. Finnegan LP, Amass L, Jones H, Kaltenbach K. Addiction and pregnancy. Heroin Addict Relat Clin Probl 2005;7(4):5-21.
  106. Welle-Strand GK. Upublisert forskningsmateriale fra Seraf. 2011.
  107. Tuten M, Jones HE. A partner's drug-using status impacts women's drug treatment outcome. Drug Alcohol Depend 2003;70(3):327-30.
  108. Tuten M, Jones HE, Tran G, Svikis DS. Partner violence impacts the psychosocial and psychiatric status of pregnant, drug-dependent women. Addict Behav 2004;29(5):1029-34.
  109. Velez ML, Montoya ID, Jansson LM, Walters V, Svikis D, Jones HE, et al. Exposure to violence among substance-dependent pregnant women and their children. J Subst Abuse Treat 2006;30(1):31-8.
  110. Bakken K, Landheim AS, Vaglum P. Axis I and II disorders as long-term predictors of mental distress: a six-year prospective follow-up of substance-dependent patients. BMC Psychiatry 2007;7:29.
  111. Bakken K, Landheim AS, Vaglum P. Substance-dependent patients with and without social anxiety disorder: occurrence and clinical differences. A study of a consecutive sample of alcohol-dependent and poly-substance-dependent patients treated in two counties in Norway. Drug Alcohol Depend 2005;80(3):321-8.
  112. Landheim AS, Bakken K, Vaglum P. Impact of comorbid psychiatric disorders on the outcome of substance abusers: a six year prospective follow-up in two Norwegian counties. BMC Psychiatry 2006;6:44.
  113. Waal H, Helgeland I. Straff, opplæring, oppdragelse og behandling. En integrert modell for ungdom med atferdsvansker. Tidsskr Nor Lægeforen 1989;109(14):1513-6.
  114. Forskrift om individuell plan etter helselovgivningen og sosialtjenesteloven. FOR 2004-12-23 nr 1837.
  115. Individuell plan 2007: veileder til forskrift om individuell plan. Oslo: Sosial- og helsedirektoratet; 2007.
  116. Nolan ML. Aims, processes and problems of antenatal education as identified by three groups of childbirth teachers. Midwifery 1997;3(4):179-88.
  117. Goodman G, Hans SL, Cox SM. Attachment behavior and its antecedents in offspring born to methadone-maintained women. J Clin Child Psychol 1999;28(1):58-69.
  118. Velez ML, Jansson LM, Montoya ID, Schweitzer W, Golden A, Svikis D. Parenting knowledge among substance abusing women in treatment. J Subst Abuse Treat 2004;27(3):215-22.
  119. Hjerkinn B, Rosvold EO, Lindbaek M. Neonatal findings among children of substance-abusing women attending a special child welfare clinic in Norway. Scand J Public Health 2009;37(7):751-7.
  120. Hjerkinn B, Lindbaek M, Skogmo I, Rosvold EO. Neuropsychological screening of children of substance-abusing women attending a Special Child Welfare Clinic in Norway. Subst Abuse Treat Prev Policy 2010;5:17.
  121. Day K, Porter A, Clarke A, Allen D, Moselhy H, Copello A. Drug misuse in pregnancy: the impact of a specialist treatment service. Psychiatri Bull 2003;27(3):99-101.
  122. Tiltak overfor gravide rusmiddelmisbrukere. Oslo: Sosial- og helsedepartementet og Barne- og familiedepartementet; 1995.
  123. Carroll KM, Chang G, Behr H, Clinton B. Improving treatment outcome in pregnant, methadone-maintained women: Results from a randomized clinical trial. Am J Addict 1995;4(1):-59.
  124. Chang G, Carroll KM, Behr HM, Kosten TR. Improving treatment outcome in pregnant opiate-dependent women. J Subst Abuse Treat 1992;9(4):327-30.
  125. Giles W, Patterson T, Sanders F, Batey R, Thomas D, Collins J. Outpatient methadone programme for pregnant heroin using women. Aust N Z J Obstet Gynaecol 1989;29(3 Pt 1):225-9.
  126. Burns L, Mattick RP, Lim K, Wallace C. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction 2007;102(2):264-70.
  127. Edelin KC, Gurganious L, Golar K, Oellerich D, Kyei-Aboagye K, Adel HM. Methadone maintenance in pregnancy: consequences to care and outcome. Obstet Gynecol 1988;71(3 Pt 1):399-404.
  128. Kandall SR, Doberczak TM, Jantunen M, Stein J. The methadone-maintained pregnancy. Clin Perinatol 1999;26(1):173-83.
  129. Haug K, Irgens LM, Skjaerven R, Markestad T, Baste V, Schreuder P. Maternal smoking and birthweight: effect modification of period, maternal age and paternal smoking. Acta Obstet Gynecol Scand 2000;79(6):485-9.
  130. Waal H, Clausen T, Håseth A, Lillevold P. Siste år med gamle retningslinjer: statusrapport 2009. Oslo: Senter for rus- og avhengighetsforskning; 2010. Seraf rapport 1/2010. Tilgjengelig fra: http://www.med.uio.no/klinmed/forskning/sentre/seraf/publikasjoner/rapporter/2010/SERAF-rapport-nr-1-2010-Statusrapport-2009-revidert.pdf
  131. Eskild A, Samdal HH, Skaug K, Jeansson S, Stray-Pedersen B, Jenum PA. Hepatitt C-virus blant gravide kvinner i Norge--forekomst av antistoffer og svangerskapsutfall. Tidsskr Nor Lægeforen 2000;120(9):1006-8.
  132. Samdal HH, Blystad H, Eskild A, Fjaerli HO, Nordbo SA, Stray-Pedersen B, et al. Hepatitt C-virusinfeksjon hos gravide og barn i Norge. Tidsskr Nor Lægeforen 2000;120(9):1047-50.
  133. Rojahn A, Wathne KO. Hepatitt C hos barn--diagnostikk, oppfølging og behandling. Tidsskr Nor Lægeforen 2002;122(20):1985-8.
  134. Wejstal R, Hermodsson S, Iwarson S, Norkrans G. Mother to infant transmission of hepatitis C virus infection. J Med Virol 1990;30(3):178-80.
  135. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105(2):94-8.
  136. Sehgal A, Sehgal R, Gupta I, Bhakoo ON, Ganguly NK. Use of hepatitis B vaccine alone or in combination with hepatitis B immunoglobulin for immunoprophylaxis of perinatal hepatitis B infection. J Trop Pediatr 1992;38:247-51.
  137. Blystad H. Smittevernhåndbok for kommunehelsetjenesten 2002-2003. Oslo: Statens folkehelseinstitutt; 2001. Smittevern h. 5.
  138. Krook AL, Stokka D, Heger B, Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 2007;13(4):216-21.
  139. Utviklingsstrategi for jordmortjenesten: tjenestekvalitet og kapasitet. Oslo: Helsedirektoratet; 2010. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/utviklingsstrategi-for-jordmortjenesten-tjenestekvalitet-og-kapasitet/Publikasjoner/utviklingsstrategi-for-jordmortjenesten-tjenestekvalitet-og-kapasitet.pdf .
  140. Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis 1999;18(4):51-61.
  141. Drozdick J, III, Berghella V, Hill M, Kaltenbach K. Methadone trough levels in pregnancy. Am J Obstet Gynecol 2002;187(5):1184-8.
  142. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985;233(1):1-6.
  143. Kreek MJ. Methadone disposition during the perinatal period in humans. Pharmacol Biochem Behav 1979;11 Suppl:7-13.
  144. Verebely K, Volavka J, Mule S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975;18(2):180-90.
  145. Wolff K, Boys A, Rostami-Hodjegan A, Hay A, Raistrick D. Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 2011;61(10):763-8.
  146. DePetrillo PB, Rice JM. Methadone dosing and pregnancy: impact on program compliance. Int J Addict 1995;30(2):207-17.
  147. Wittmann BK, Segal S. A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation. Int J Addict 1991;26(2):213-8.
  148. Jansson LM, Dipietro JA, Velez M, Elko A, Knauer H, Kivlighan KT. Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med 2009;22(1):29-35.
  149. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: Effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79(1):1-10.
  150. Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson LM, et al. Buprenorphine treatment of pregnant opioid-dependent women: Maternal and neonatal outcomes. Drug Alcohol Depend 2001;63(1):97-103.
  151. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004;99(2):209-14.
  152. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70(2 Suppl):S87-101.
  153. Jones HE, Johnson RE, Jasinski DR, Milio L. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend 2005;78(1):33-8.
  154. Unger A, Jagsch R, Jones H, Arria A, Leitich H, Rohrmeister K, et al. Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison. Addiction 2011;106(7):1355-62.
  155. Ramirez-Cacho WA, Flores S, Schrader RM, McKay J, Rayburn WF. Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. J Soc Gynecol Investig 2006;13(2):108-11.
  156. Anyaegbunam A, Tran T, Jadali D, Randolph G, Mikhail MS. Assessment of fetal well-being in methadone-maintained pregnancies: abnormal nonstress tests. Gynecol Obstet Invest 1997;43(1):25-8.
  157. Jansson LM, Dipietro J, Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol 2005;193(3 Pt 1):611-7.
  158. Richardson BS, O'Grady JP, Olsen GD. Fetal breathing movements and the response to carbon dioxide in patients on methadone maintenance. Am J Obstet Gynecol 1984;150(4):400-5.
  159. Wouldes TA, Roberts AB, Pryor JE, Bagnall C, Gunn TR. The effect of methadone treatment on the quantity and quality of human fetal movement. Neurotoxicol Teratol 2004;26(1):23-34.
  160. Schmid M, Kuessel L, Klein K, Metz V, Fischer G, Krampl-Bettelheim E. First-trimester fetal heart rate in mothers with opioid addiction. Addiction 2010;105(7):1265-8.
  161. Whitham JN, Spurrier NJ, Sawyer MG, Baghurst PA, Taplin JE, White JM, et al. The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicol Teratol 2010;32(2):280-8.
  162. Jones HE, Suess P, Jasinski DR, Johnson RE. Transferring methadone-stabilized pregnant patients to buprenorphine using an immediate release morphine transition: an open-label exploratory study. Am J Addict 2006;15(1):61-70.
  163. Nationella riktlinjer för missbruks- och beroendevård: vägledning för socialtjänstens och hälso- och sjukvårdens verksamhet för personer med missbruks- och beroendeproblem. Stockholm: Socialstyrelsen; 2007. Tilgjengelig fra: http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/8933/2007-102-1_20071021_rev.pdf .
  164. Guidance No. 42 on Medical Treatment of Drug Abusers in Substitution Treatment for Opioid Dependence. København: Sundhedsstyrelsen; 2008. Tilgjengelig fra: http://www.sst.dk/publ/Publ2008/EFT/Substitbehl_en/Guide_Substtreatm_Drugabuse.pdf .
  165. Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003;189(2):312-7.
  166. McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005;193(3 Pt 1):606-10.
  167. Mack G, Thomas D, Giles W, Buchanan N. Methadone levels and neonatal withdrawal. J Paediatr Child Health 1991;27(2):96-100.
  168. Rosen TS, Pippenger CE. Pharmacologic observations on the neonatal withdrawal syndrome. J Pediatr 1976;88(6):1044-8.
  169. Brown HL, Britton KA, Mahaffey D, Brizendine E, Hiett AK, Turnquest MA. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol 1998;179(2):459-63.
  170. Seligman NS, Almario CV, Hayes EJ, Dysart KC, Berghella V, Baxter JK. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr 2010;157(3):428-33, 433.
  171. Pizarro D, Habli M, Grier M, Bombrys A, Sibai B, Livingston J. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. J Subst Abuse Treat 2011;40(3):295-8.
  172. Kandall SR, Doberczak TM, Mauer KR, Strashun RH, Korts DC. Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. Am J Dis Child 1983;137(4):378-82.
  173. Malpas TJ, Darlow BA, Lennox R, Horwood LJ. Maternal methadone dosage and neonatal withdrawal. Aust N Z J Obstet Gynaecol 1995;35(2):175-7.
  174. Harper RG, Solish G, Feingold E, Gersten-Woolf NB, Sokal MM. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. Am J Obstet Gynecol 1977;129(4):417-24.
  175. Doberczak TM, Kandall SR, Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993;81(6):936-40.
  176. Mayes LC, Carroll KM. Neonatal withdrawal syndrome in infants exposed to cocaine and methadone. Subst Use Misuse 1996;31(2):241-53.
  177. Dashe JS, Sheffield JS, Olscher DA, Todd SJ, Jackson GL, Wendel GD, Jr. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002;100(6):1244-9.
  178. Lim S, Prasad MR, Samuels P, Gardner DK, Cordero L. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009;200(1):70-5.
  179. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009;116(5):665-71.
  180. Wouldes TA, Woodward LJ. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol 2010;32(3):406-13.
  181. Cleary BJ, Donnelly JM, Strawbridge JD, Gallagher PJ, Fahey T, White MJ, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011;204(2):139.
  182. Cleary BJ, Donnelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M, et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010;105(12):2071-84.
  183. Gray TR, Choo RE, Concheiro M, Williams E, Elko A, Jansson LM, et al. Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. Addiction 2010;105(12):2151-9.
  184. Velez ML, Jansson LM, Schroeder J, Williams E. Prenatal methadone exposure and neonatal neurobehavioral functioning. Pediatr Res 2009;66(6):704-9.
  185. Doberczak TM, Thornton JC, Bernstein J, Kandall SR. Impact of maternal drug dependency on birth weight and head circumference of offspring. Am J Dis Child 1987;141(11):1163-7.
  186. Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976;58(5):681-5.
  187. Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Fetal and postnatal growth of children born to narcotic-dependent women. J Pediatr 1983;102(5):686-91.
  188. Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997;92(11):1571-9.
  189. Lund LK, Vik T, Skranes J, Brubakk AM, Indredavik MS. Psychiatric morbidity in two low birth weight groups assessed by diagnostic interview in young adulthood. Acta Paediatr 2011;100(4):598-604.
  190. Blinick G, Wallach RC, Jerez E. Pregnancy in narcotics addicts treated by medical withdrawal. The methadone detoxification program. Am J Obstet Gynecol 1969;105(7):997-1003.
  191. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003;24(4):363-7.
  192. Newman RG. Letter to editor: Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2004;26(2):65-6.
  193. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD, Jr. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92(5):854-8.
  194. Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008;17(5):372-86.
  195. Strauss ME, Starr RH, Ostrea EM, Chavez CJ, Stryker JC. Behavioural concomitants of prenatal addiction to narcotics. J Pediatr 1976;89(5):842-6.
  196. Blinick G, Wallach RC, Jerez E, Ackerman BD. Drug addiction in pregnancy and the neonate. Am J Obstet Gynecol 1976;125(2):135-42.
  197. McCarthy JE, Siney C, Shaw NJ, Ruben SM. Outcome predictors in pregnant opiate and polydrug users. Eur J Pediatr 1999;158(9):748-9.
  198. Eklund C. Withdrawal from methadone maintenance treatment in Sweden [doktoravhandling]. Uppsala: Acta Universitatis Upsaliensis; 1996.
  199. Clausen T, Anchersen K, Waal H. Mortality prior to,during and after opioid maintenance treatment (OMT):A national prospective cross-registry study. Drug Alcohol Depend 2008;94:151-7.
  200. Kvalitetsrutiner ved rusmiddeltesting av prøver i medisinsk sammenheng. Oslo: Sosial- og helsedirektoratet; 2002. Rundskriv IS-13/2002.
  201. Kvalitetskrav til rutiner for rusmiddeltesting, hvor positivt analysesvar kan danne grunnlag for iverksetting av alvorlige sanksjoner. Oslo: Sosial- og helsedirektoratet; 2002. Rundskriv IS-14/2002.
  202. Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010;19(4):408-17.
  203. Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict 2010;19(1):59-72.
  204. Legemidler og svangerskap: beroligende medisiner kan være farlig for fosteret [Nettdokument]. Oslo: Folkehelseinstituttet [oppdatert 18 Apr 2011; lest 29 Dec 2011]. Tilgjengelig fra: http://www.fhi.no/eway/default.aspx?pid=233&trg=MainLeft_5565&MainArea_5661=5565:0:15,2336:1:0:0:::0:0&MainLeft_5565=5544:54688::1:5567:12:::0:0
  205. Alkohol og graviditet: hva er farlig for fosteret? hvordan forebygge og behandle? Rapport fra en ekspertgruppe. Oslo: Sosial- og helsedirektoratet; 2005. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/alkohol-og-graviditet/Publikasjoner/alkohol-og-graviditet.pdf .
  206. Alvik A, Heyerdahl S, Haldorsen T, Lindemann R. Alcohol use before and during pregnancy: a population-based study. Acta Obstet Gynecol Scand 2006;85(11):1292-8.
  207. Alvik A, Haldorsen T, Lindemann R. Alcohol consumption, smoking and breastfeeding in the first six months after delivery. Acta Paediatr 2006;95(6):686-93.
  208. Alvik A, Haldorsen T, Groholt B, Lindemann R. Alcohol consumption before and during pregnancy comparing concurrent and retrospective reports. Alcohol Clin Exp Res 2006;30(3):510-5.
  209. Alvik A, Haldorsen T, Lindemann R. Consistency of reported alcohol use by pregnant women: anonymous versus confidential questionnaires with item nonresponse differences. Alcohol Clin Exp Res 2005;29(8):1444-9.
  210. Russell M, Martier SS, Sokol RJ, Mudar P, Bottoms S, Jacobson S, et al. Screening for pregnancy risk-drinking. Alcohol Clin Exp Res 1994;18(5):1156-61.
  211. Burns E, Gray R, Smith LA. Brief screening questionnaires to identify problem drinking during pregnancy: a systematic review. Addiction 2010;105(4):601-14.
  212. TWEAK (med tilleggsspørsmål). Oslo: Helsedirektoratet; 2011. TWEAK spørreskjema oversatt til norsk av Alvik A. og Ueland T. Tilgjengelig fra: http://www.helsebiblioteket.no/_attachment/108221
  213. Arlettaz R, Kashiwagi M, Das-Kundu S, Fauchere JC, Lang A, Bucher HU. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 2005;84(2):145-50.
  214. Ebner N, Rohrmeister K, Winklbaur B, Baewert A, Jagsch R, Peternell A, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007;87(2-3):131-8.
  215. Dybing E, Sanner T. Passive smoking, sudden infant death syndrome (SIDS) and childhood infections. Hum Exp Toxicol 1999;18(4):202-5.
  216. Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2009;(3):CD001055.
  217. Choo RE, Huestis MA, Schroeder JR, Shin AS, Jones HE. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004;75(3):253-60.
  218. Stene-Larsen K, Borge AI, Vollrath ME. Maternal smoking in pregnancy and externalizing behavior in 18-month-old children: results from a population-based prospective study. J Am Acad Child Adolesc Psychiatry 2009;48(3):283-9.
  219. Ortendahl M, Nasman P. Factors affecting continuation of smoking by pregnant and nonpregnant women. Subst Abus 2009;30(2):150-7.
  220. Nasjonal faglig retningslinje for røykeavvenning i primærhelsetjenesten. Oslo: Sosial- og helsedirektoratet; 2004. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/nasjonal-faglig-retning-for-roykeavvenning-i-primerhelsetjenesten/Publikasjoner/nasjonal-faglig-retning-for-roykeavvenning-i-primerhelsetjenesten.pdf .
  221. Steiro A, Smedslund G, Hammerstrøm KT. Tiltak for å redusere røyking, spesielt i grupper med lav sosioøkonomisk status. Oslo: Kunnskapssenteret; 2007. Rapport fra Kunnskapssenteret 13 - 2007. Tilgjengelig fra: http://www.kunnskapssenteret.no/Publikasjoner/926.cms
  222. Sæterdal I, Ringerike T, Odegaard-Jensen J, Harboe I, Hagen G, Reikvam A, et al. Legemidler til røykeslutt. Oslo: Kunnskapssenteret; 2010. Rapport fra Kunnskapssenteret 8 - 2010. Tilgjengelig fra: http://www.kunnskapssenteret.no/Publikasjoner/9188.cms
  223. Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2010;(1):CD006936.
  224. Coleman T, Chamberlain C, Cooper S, Leonardi-Bee J. Efficacy and safety of nicotine replacement therapy for smoking cessation in pregnancy: systematic review and meta-analysis. Addiction 2011;106(1):52-61.
  225. Chisolm MS, Brigham EP, Lookatch SJ, Tuten M, Strain EC, Jones HE. Cigarette smoking knowledge, attitudes, and practices of patients and staff at a perinatal substance abuse treatment center. J Subst Abuse Treat 2010;39(3):298-305.
  226. Sagbakken M, Vik M. Røykesluttprogram for gravide. Oslo: Sosial- og helsedirektoratet; 2004. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/roykesluttprogram-for-gravide/Publikasjoner/roykesluttprogram-for-gravide.pdf .
  227. Haug K, Aaro LE, Fugelli P. Pregnancy--a golden opportunity for promoting the cessation of smoking? Scand J Prim Health Care 1994;12(3):184-9.
  228. Eriksen W, Sorum K, Bruusgaard D. Is there an increased lability in parents' smoking behaviour after a childbirth? Scand J Prim Health Care 1996;14(2):86-91.
  229. Å snakke om endring: kommunikasjonsverktøy for helsepersonell som jobber med røykeslutt. Oslo: Helsedirektoratet; 2009. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/a-snakke-om-endring-kommunikasjonsverktoy-for-helsepersonell-som-jobber-med-roykeslutt/Publikasjoner/a-snakke-om-endring-kommunikasjonsverktoy-for-helsepersonell-som-jobber-med-roykeslutt.pdf .
  230. Terplan M, Lui S. Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev 2007;(4):CD006037.
  231. Simmat-Durand L, Lejeune C, Gourarier L. Pregnancy under high-dose buprenorphine. Eur J Obstet Gynecol Reprod Biol 2009;142(2):119-23.
  232. Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat 2007;32(1):19-25.
  233. Tuten M, Jones HE, Svikis DS. Comparing homeless and domiciled pregnant substance dependent women on psychosocial characteristics and treatment outcomes. Drug Alcohol Depend 2003;69(1):95-9.
  234. Moylan PL, Jones HE, Haug NA, Kissin WB, Svikis DS. Clinical and psychosocial characteristics of substance-dependent pregnant women with and without PTSD. Addict Behav 2001;26(3):469-74.
  235. Grencavage LM, Norcross J. Where are the commonalities among the therapeutic common factors? Professional Psychology Research and Practice 1990;21(5):372-8.
  236. Hubble MA, Duncan BL, Miller SD, red. The heart & soul of change: what works in therapy? Washington, D.C.: American Psychological Association; 1999.
  237. Lambert MJ. Implications of outcome research for psychotherapy integration. I: Norcross J, Gombas W, red. Handbook of psychotherapy integration. New York: Basic books; 1992. s. 94-129.
  238. Sundet R. Brukerperspektivet og den terapeutiske relasjon - betydninger for terapeutisk arbeid. I: Ulvestad AK, Henriksen AK, Tuseth A-G, Fjeldstad T, red. Klienten - den glemte terapeut: brukerstyring i psykisk helsearbeid. Oslo: Gyldendal; 2007. s. 312-27.
  239. Daley M, Argeriou M, McCarty D. Substance abuse treatment for pregnant women: a window of opportunity? Addict Behav 1998;23(2):239-49.
  240. Brooner RK, Kidorf MS, King VL, Stoller KB, Peirce JM, Bigelow GE, et al. Behavioral contingencies improve counseling attendance in an adaptive treatment model. J Subst Abuse Treat 2004;27(3):223-32.
  241. Veileder for vurdering av henvisning til tverrfaglig spesialisert behandling. Oslo: Helsedirektoratet; 2008. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/vurdering-av-henvisninger-til-tverrfaglig-spesialisert-rusbehandling-/Publikasjoner/vurdering-av-henvisninger-til-tverrfaglig-spesialisert-rusbehandling-konvertert.pdf .
  242. Distriktspsykiatriske sentre: med blikket vendt mot kommunene og spesialiserte sykehusfunksjoner i ryggen. Oslo: Sosial- og helsedirektoratet; 2006.
  243. Lundeberg IR, Mjåland K, Søvig KH, Nilssen E, Ravneberg B. Tvang overfor rusmiddelavhengige: evaluering av Lov om sosiale tjenesters §§ 6-2, 6-2a og 6-3. Bergen: Uni Rokkansenteret, Stein Rokkan senter for flerfaglige samfunnsstudier; 2010. Rapport 2-2010. Tilgjengelig fra: http://rokkan.uni.no/rPub/files/269_Rapport_2-2010_Lundeberg,_Mjaland,_Sovig,_Nilssen_og_Ravneberg.pdf
  244. Almario CV, Seligman NS, Dysart KC, Berghella V, Baxter JK. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol 2009;201(3):326.
  245. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006;144(2):127-34.
  246. Mehta V, Langford RM. Acute pain management for opioid dependent patients. Anaesthesia 2006;61(3):269-76.
  247. Meyer M, Wagner K, Benvenuto A, Plante D, Howard D. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007;110(2 Pt 1):261-6.
  248. Jones HE, O'Grady K, Dahne J, Johnson R, Lemoine L, Milio L, et al. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse 2009;35(3):151-6.
  249. Finnegan LP, Connaughton JF, Jr., Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2(1-2):141-58.
  250. Levy M, Spino M. Neonatal withdrawal syndrome: associated drugs and pharmacologic management. Pharmacotherapy 1993;13(3):202-11.
  251. Binder T, Vavrinkova B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008;29(1):80-6.
  252. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1998;101(6):1079-88.
  253. Quick ZL, Robb MP, Woodward LJ. Acoustic cry characteristics of infants exposed to methadone during pregnancy. Acta Paediatr 2009;98(1):74-9.
  254. Kaltenbach K, Finnegan LP. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav Toxicol Teratol 1986;8(4):353-5.
  255. Kuschel CA, Austerberry L, Cornwell M, Couch R, Rowley RS. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch Dis Child Fetal Neonatal Ed 2004;89(5):F390-F393.
  256. Jansson LM, Dipietro JA, Elko A, Velez M. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med 2007;20(9):677-85.
  257. Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, Baxter JK. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008;199(4):396-7.
  258. Rohrmeister K, Bernert G, Langer M, Fischer G, Weninger M, Pollak A. Opiatabhangigkeit in der Schwangerschaft - Konsequenzen fur das Neugeborene1 - Ergebnisse eines interdisziplinaren Betreuungsmodells. Z Geburtshilfe Neonatol 2001;205(6):224-30.
  259. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 1991;118(6):933-7.
  260. Dysart K, Hsieh HC, Kaltenbach K, Greenspan JS. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007;35(4):344-6.
  261. Johnson K, Greenough A, Gerada C. Maternal drug use and length of neonatal unit stay. Addiction 2003;98(6):785-9.
  262. Jones HE, Harrow C, O'Grady KE, Crocetti M, Jansson LM, Kaltenbach K. Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison. J Opioid Manag 2010;6(6):409-13.
  263. Crocetti MT, Amin DD, Jansson LM. Variability in the evaluation and management of opiate-exposed newborns in Maryland. Clin Pediatr (Phila) 2007;46(7):632-5.
  264. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 2006;26(1):15-7.
  265. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr (Phila) 1975;14(6):592-4.
  266. Jones HE, O'Grady KE, Johnson RE, Velez M, Jansson LM. Infant neurobehavior following prenatal exposure to methadone or buprenorphine: results from the neonatal intensive care unit network neurobehavioral scale. Subst Use Misuse 2010;45(13):2244-57.
  267. Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010;(10):CD002053.
  268. Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010;(10):CD002059.
  269. Langenfeld S, Birkenfeld L, Herkenrath P, Muller C, Hellmich M, Theisohn M. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend 2005;77(1):31-6.
  270. Kuschel C. Managing drug withdrawal in the newborn infant. Semin Fetal Neonatal Med 2007;12(2):127-33.
  271. Finnegan L. Management of maternal and neonatal substance abuse problems. NIDA Res Monogr 1988;90:177-82.
  272. Velez M, Jansson LM. The Opioid dependent mother and newborn dyad: non-pharmacologic care. J Addict Med 2008;2(3):113-20.
  273. Wachman EM, Byun J, Philipp BL. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med 2010;5(4):159-64.
  274. Kron RE, Litt M, Eng D, Phoenix MD, Finnegan LP. Neonatal narcotic abstinence: Effects of pharmacotherapeutic agents and maternal drug usage on nutritive sucking behavior. J Pediatr 1976;88(4 Pt 1):637-41.
  275. Jansson LM, Choo RE, Harrow C, Velez M, Schroeder JR, Lowe R, et al. Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact 2007;23(2):184-90.
  276. Jansson LM, Choo R, Velez ML, Harrow C, Schroeder JR, Shakleya DM, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008;121(1):106-14.
  277. Lindemalm S, Nydert P, Svensson JO, Stahle L, Sarman I. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact 2009;25(2):199-205.
  278. Moss N, Hval M, Hellerud A, Petersen I. Samspillsveileder: styrking av samspill mellom premature barn og deres foreldre basert på NIDCAP-prinsippene og Vermont-programmet. Drammen: Sykehuset Buskerud HF; 2007.
  279. Killén K. Risiko - omsorgssvikt - samspill - tilknytning: opplæring og metodeutvikling: rapport til Helsedirektoratet og Kompetansesenter rus - region sør, Borgestadklinikken. Skien og Oslo: Kompetansesenter rus - region sør, Borgestadklinikken Blå kors forl.; 2011.
  280. Killén K. Risiko - omsorgssvikt - samspill - tilknytning: opplærings- og utviklingsarbeid i behandling av foreldre-barn med rus- og psykiske problemer og andre alvorlige psykososiale belastninger. Skien og Oslo: Kompetansesenter rus - region sør, Borgestadklinikken Blå kors forl.; 2010.
  281. Söderström K. Tidlig intervensjon overfor små barn i psykososial risiko. I: Straand S, red. Samhandling som omsorg: tverrfaglig psykososialt arbeid med barn og unge. Oslo: Kommuneforlaget; 2011. s. 158-75.
  282. Jones HE, Johnson RE, O'Grady KE, Jasinski DR, Tuten M, Milio L. Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. J Addict Med 2008;2(2):103-7.
  283. McGlade A, Ware R, Crawford M. Child protection outcomes for infants of substance-using mothers: a matched-cohort study. Pediatrics 2009;124(1):285-93.
  284. Hans SL. Developmental consequences of prenatal exposure to methadone. Ann N Y Acad Sci 1989;562:195-207.
  285. Hviding K. Kartleggingsverktøy og instrumenter for tidlig avdekking av utviklings-, atferds- og psyososiale vansker hos barn 0-6 år. Oslo: Kunnskapssenteret; 2005. Rapport fra Kunnskapssenteret 10-2005. Tilgjengelig fra: http://www.kunnskapssenteret.no/Publikasjoner/1198.cms
  286. Nelson LB, Ehrlich S, Calhoun JH, Matteucci T, Finnegan LP. Occurrence of strabismus in infants born to drug-dependent women. Am J Dis Child 1987;141(2):175-8.
  287. Hamilton R, McGlone L, MacKinnon JR, Russell HC, Bradnam MS, Mactier H. Ophthalmic, clinical and visual electrophysiological findings in children born to mothers prescribed substitute methadone in pregnancy. Br J Ophthalmol 2010;94(6):696-700.
  288. Forskrift om pasientjournal. FOR 2000-12-21 nr 1385.
  289. Kunnskapsdepartementet. Kvalitet i barnehagen. St.meld. nr 41 (2008-2009). Tilgjengelig fra: http://www.regjeringen.no/pages/2197014/PDFS/STM200820090041000DDDPDFS.pdf
  290. Fordelingsutvalget. Oslo: Departementenes servicesenter, Informasjonsforvaltning; 2009. NOU 2009:10. Tilgjengelig fra: http://www.regjeringen.no/pages/2185274/PDFS/NOU200920090010000DDDPDFS.pdf
  291. Elgen I, Bruaroy S, Laegreid LM. Complexity of foetal alcohol or drug neuroimpairments. Acta Paediatr 2007;96(12):1730-3.
  292. Veileder for poliklinikker i psykisk helsevern for barn og unge. Oslo: Helsedirektoratet; 2008. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/psykisk-helsevern-for-barn-og-unge-veileder-for-poliklinikker/Publikasjoner/psykisk-helsevern-for-barn-og-unge-veileder-for-poliklinikker.pdf .
  293. Hansen MB, Jacobsen H. Sped- og småbarn i risiko: en kunnskapsstatus. Oslo: Regionsenter for barn og unges psykiske helse. Helseregion Øst og Sør; 2008. Tilgjengelig fra: http://www.r-bup.no/CMS/CMSpublish.nsf/BA82C070A47CA97EC12574F9003DCCC7/$file/Tiltak42.pdf .
  294. Sandbæk M, red. Familiers inntekt og barns levekår over tid. Oslo: Nova; 2008. Nova rapport 7/08. Tilgjengelig fra: http://www.nova.no/asset/3379/1/3379_1.pdf
  295. Li L, Levine B, Smialek JE. Fatal methadone poisoning in children: Maryland 1992-1996. Subst Use Misuse 2000;35(9):1141-8.
  296. Boyer EW, McCance-Katz EF, Marcus S. Methadone and buprenorphine toxicity in children. Am J Addict 2009;19(1):89-95.
  297. Eyler FD, Behnke M. Early development of infants exposed to drugs prenatally. Clin Perinatol 1999;26(1):107-50, vii.
  298. Hunt RW, Tzioumi D, Collins E, Jeffery HE. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008;84(1):29-35.
  299. Marcus J, Hans SL, Jeremy RJ. Differential motor and state functioning in newborns of women on methadone. Neurobehav Toxicol Teratol 1982;4(4):459-62.
  300. Marcus J, Hans SL, Jeremy RJ. Patterns of 1-day and 4-month motor functioning in infants of women on methadone. Neurobehav Toxicol Teratol 1982;4(4):473-6.
  301. Bernstein V, Jeremy RJ, Hans SL, Marcus J. A longitudinal study of offspring born to methadone-maintained women. II. Dyadic interaction and infant behavior at 4 months. Am J Drug Alcohol Abuse 1984;10(2):161-93.
  302. Jeremy RJ, Bernstein VJ. Dyads at risk: methadone-maintained women and their four-month-old infants. Child Dev 1984;55(4):1141-54.
  303. Bernstein VJ, Hans SL. Predicting the development outcome of two-year-old children born exposed to methadone: Impact of social-environmental risk factors. J Clin Child Psychol 1994;23:349-59.
  304. Schneider JW, Hans SL. Effects of prenatal exposure to opioids on focused attention in toddlers during free play. J Dev Behav Pediatr 1996;17(4):240-7.
  305. Hans SL, Jeremy RJ. Postneonatal mental and motor development of infants exposed in utero to opioid drugs. Infant Ment Health J 2001;22(3):300-15.
  306. Goodman G, Hans SL, Bernstein VJ. Mother expectation of bother and infant attachment behaviors of mother and child communication at 24 months in children of methadone-maintained women. Infant Ment Health J 2005;26(6):549-69.
  307. Finnegan LP, Reeser DS, Connaughton JF, Jr. The effects of maternal drug dependence on neonatal mortality. Drug Alcohol Depend 1977;2(2):131-40.
  308. Kaltenbach K, Finnegan LP. Perinatal and developmental outcome of infants exposed to methadone in-utero. NIDA Res Monogr 1987;76:276.
  309. Kaltenbach K, Finnegan LP. Children exposed to methadone in utero. Assessment of developmental and cognitive ability. Ann N Y Acad Sci 1989;360-2.
  310. Rosen TS, Johnson HL. Children of methadone-maintained mothers: follow-up to 18 months of age. J Pediatr 1982;101(2):192-6.
  311. Johnson HL, Rosen TS. Prenatal methadone exposure: effects on behavior in early infancy. Pediatr Pharmacol (New York ) 1982;2(2):113-20.
  312. Rosen TS, Johnson HL. Long-term effects of prenatal methadone maintenance. NIDA Res Monogr 1985;59:73-83.
  313. Johnson HL, Glassman MB, Fiks KB, Rosen TS. Resilient children: individual differences in developmental outcome of children born to drug abusers. J Genet Psychol 1990;151(4):523-39.
  314. Strauss ME, Andresko M, Stryker JC, Wardell JN. Relationship of neonatal withdrawal to maternal methadone dose. Am J Drug Alcohol Abuse 1976;3(2):339-45.
  315. Strauss ME, Lessen-Firestone JK, Chavez CJ, Stryker JC. Children of methadone-treated women at five years of age. Pharmacol Biochem Behav 1979;11 Suppl:3-6.
  316. Wilson GS, Desmond MM, Wait RB. Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. J Pediatr 1981;98(5):716-22.
  317. Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics 1985;75(2):269-74.
  318. Wilson GS. Clinical studies of infants and children exposed prenatally to heroin. Ann N Y Acad Sci 1989;562:183-94.
  319. Chasnoff IJ, Hatcher R, Burns WJ. Polydrug- and methadone-addicted newborns: a continuum of impairment? Pediatrics 1982;70(2):210-3.
  320. Chasnoff IJ, Burns KA, Burns WJ, Schnoll SH. Prenatal drug exposure: effects on neonatal and infant growth and development. Neurobehav Toxicol Teratol 1986;8(4):357-62.
  321. de Cubas MM, Field T. Children of methadone-dependent women: developmental outcomes. Am J Orthopsychiatry 1993;63(2):266-76.
  322. van Baar AL, Fleury P, Soepatmi S, Ultee CA, Wesselman PJ. Neonatal behavior after drug dependent pregnancy. Arch Dis Child 1989;64(2):235-40.
  323. van Baar AL, Fleury P, Ultee CA. Behaviour in first year after drug dependent pregnancy. Arch Dis Child 1989;64(2):241-5.
  324. Burns EC, O'Driscoll M, Wason G. The health and development of children whose mothers are on methadone maintenance. Child Abuse Rev 1996;5(2):113-22.
  325. Lester BM. The Maternal Lifestyles Study. Ann N Y Acad Sci 1998;846:296-305.
  326. Lester BM, Tronick EZ, Lagasse L, Seifer R, Bauer CR, Shankaran S, et al. The maternal lifestyle study: effects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants. Pediatrics 2002;110(6):1182-92.
  327. Messinger DS, Bauer CR, Das A, Seifer R, Lester BM, LaGasse LL, et al. The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics 2004;113(6):1677-85.
  328. Sheinkopf SJ, Lester BM, LaGasse LL, Seifer R, Bauer CR, Shankaran S, et al. Interactions between maternal characteristics and neonatal behavior in the prediction of parenting stress and perception of infant temperament. J Pediatr Psychol 2006;31(1):27-40.
  329. Shankaran S, Lester BM, Das A, Bauer CR, Bada HS, Lagasse L, et al. Impact of maternal substance use during pregnancy on childhood outcome. Semin Fetal Neonatal Med 2007;12(2):143-50.
  330. Bagner DM, Sheinkopf SJ, Miller-Loncar C, LaGasse LL, Lester BM, Liu J, et al. The effect of parenting stress on child behavior problems in high-risk children with prenatal drug exposure. Child Psychiatry Hum Dev 2009;40(1):73-84.
  331. Stone KC, High PC, Miller-Loncar CL, LaGasse LL, Lester BM. Longitudinal study of maternal report of sleep problems in children with prenatal exposure to cocaine and other drugs. Behav Sleep Med 2009;7(4):196-207.
  332. Whitaker TM, Bada HS, Bann CM, Shankaran S, Lagasse L, Lester BM, et al. Serial Pediatric Symptom Checklist Screening in Children With Prenatal Drug Exposure. J Dev Behav Pediatr 2011;32(3):206-15.
  333. Stone KC, LaGasse LL, Lester BM, Shankaran S, Bada HS, Bauer CR, et al. Sleep problems in children with prenatal substance exposure: the Maternal Lifestyle study. Arch Pediatr Adolesc Med 2010;164(5):452-6.
  334. Lester BM, Miller RJ, Hawes K, Salisbury A, Bigsby R, Sullivan MC, et al. Infant neurobehavioral development. Semin Perinatol 2011;35(1):8-19.
  335. Lester BM, LaGasse LL. Children of addicted women. J Addict Dis 2010;29(2):259-76.
  336. Hulse GK, Milne E, English DR, Holman CD. Assessing the relationship between maternal opiate use and neonatal mortality. Addiction 1998;93(4):1033-42.